Showing 1‐6 of 6
results per page
07 Oct 2021
Lonza to Expand Development Services for Mammalian Products in Singapore
As part of continued investment in Asia, Lonza is expanding mammalian development services at its Singapore facility This expansion will support the global operations...
21 Sep 2021
Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
Triumvira's T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza's Cocoon® platform at the C3i Center Inc (C3i) in Montreal...
12 Aug 2021
Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing...
23 Jun 2021
CellPoint and Lonza to Leverage the Cocoon Platform for T-Cell Therapeutics Manufactured at the Point-of-Care
CellPoint and Lonza will collaborate to rapidly develop several T-cell based therapies and utilize the Cocoon® Platform for clinical point-of-care manufacturing The goal is to...
23 Apr 2021
Lonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp
Lonza will invest CHF 200 million to construct a new manufacturing complexThe 2000 m2 complex will include a customer dedicated manufacturing line...
16 Feb 2021
Lonza Expands Solid Form Services for Small Molecule Drugs
Solid Form Services encompass all aspects of solid form screening and characterization of small molecule APIsOffering designed to complement Lonza API development services and...